Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Metzler German Smaller Caompani (LQ3E.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
164.45+0.68 (+0.42%)
At close: 09:55PM CET
Advertisement
Full screen
Previous Close163.77
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (5Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • CNW Group

    Visa Canada Celebrates 2022 Grant Recipients as Optimism Grows Among Small Businesses

    Today, Visa Canada announced the 10 recipients of the third round of its She's Next Grant Program in Canada. The She's Next Grant Program supports women entrepreneurship, empowering growth and innovation, through a grant of $10,000 CAD and one-year of business coaching, in partnership with IFundWomen. Through the grant program and IFundWomen's network of women-owned businesses and mentors, recipients will gain access to funding, coaching, and connections to help expand their businesses.

  • GlobeNewswire

    Profound Medical to Release Fourth Quarter and Full Year 2021 Financial Results on March 3 – Conference Call to Follow

    TORONTO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2021 financial results after market close on Thursday, March 3, 2022. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business dev

  • GlobeNewswire

    Kenneth Knudson Joins Profound Medical as Chief Commercial Officer

    TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of accomplished global medical device industry veteran, Kenneth Knudson, as Chief Commercial Officer. Mr. Knudson’s mandate will be leading Profound’s worldwide sales, marketing and reimbursement activitie

Advertisement
Advertisement